Mohini Health (MHHL)

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• High promoter holding of 64.02% aligns management interests with minority shareholders.
• ROCE of 14.12% suggests underlying operations still generate a positive return before financing costs.
• Quarterly revenue of ₹74 Cr is large relative to the ₹72 Cr market cap, giving operating leverage potential if margins recover.

Concerns

• Sales growth is -19.58% and the latest quarter shows a net loss of ₹4 Cr, with profit growth at -181.95%.
• Piotroski F-Score of 3/9 points to poor financial health and deteriorating fundamentals.
• No book value, debt/equity, or ROE data is available, so solvency and asset backing cannot be assessed.
• A P/E of 21.65 is not credible alongside current losses, and the zero dividend yield offers no compensation while waiting.

AI Analysis

Putting my Graham/Buffett hat on, the first thing I need is clarity. Mohini Health gives me very little. The latest quarter shows ₹74 Cr of revenue but a ₹4 Cr net loss; sales have fallen 19.58%, and profit growth has collapsed by 181.95%. That is a business contracting, not compounding. An investor is asked to pay ₹40.50 per share, or ₹72 Cr market cap, for a company that cannot currently make money at the net level. The reported P/E of 21.65 is either stale or misleading; with a loss in the latest quarter, conventional earnings-based valuation loses its meaning. The Piotroski F-Score of 3/9 reinforces my suspicion: profitability, leverage, and operating efficiency are all slipping. A zero dividend yield means the small shareholder gets no cash while waiting for a recovery. Promoter holding at 64.02% does at least align owner-management interests, and ROCE of 14.12% shows operations are not completely value-destructive before financing costs. But what about the balance sheet? Book value, debt/equity, and return on equity are not available, so I cannot judge solvency risk. That is a red flag. The 52-week range of ₹29.20 to ₹56.95 tells me the stock has fallen, but a fallen stock is not automatically cheap; without earnings stability and a clean balance sheet, it can keep falling. I see no durable moat in these numbers. If Mohini can stop the revenue decline, return to positive net profit, and reveal a healthy balance sheet, it could become a turnaround. Today, the evidence is insufficient and the margin of safety is absent. I will stay within my circle of competence and pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer